Oct 30, 2023
Immutep Quarterly Activities Report Q1 FY24
Oct 25, 2023
Immutep Receives ~A$1.13 Million R&D Tax Incentive
Oct 24, 2023
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Oct 22, 2023
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Oct 15, 2023
Immutep Announces Publication of Abstracts at ESMO Congress 2023
